CagriSema

News

Martin Holst Lange, Novo Nordisk's head of development

Novo charts course ahead for CagriSema after lacklustre data

After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

Novo Nordisk sheds billions in value on obesity data

Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.

Novo charts course ahead for CagriSema after lacklustre data

11 blockbuster drugs to look out for in 2025

Novo Nordisk sheds billions in value on obesity data

Pulmonary fibrosis drug developer Avalyn files IPO

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks